What changed today in Metabolic: 7 trial updates
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records8 sources1 min read
Orforglipron
Orforglipron is an oral, non-peptide (small-molecule) GLP-1 receptor agonist developed by Eli Lilly. Its trials and regulatory status are tracked here from official sources.
Building
- Editorial attention
- Building
- Tracked this week
- 4
- Sources this week
- 2
- Last activity
- 5 days ago
Signal strength reflects editorial attention across tracked sources — not medical certainty or strength of evidence.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
Orforglipron at a glance
- About this topic
- Orforglipron is an oral, non-peptide (small-molecule) GLP-1 receptor agonist developed by Eli Lilly. Its trials and regulatory status are tracked here from official sources.
- Current status
- No editor-reviewed status summary yet. The official records below update automatically.
- Last updated
- Primary sources
- Latest official record: Trial status changed to “Recruiting”: ACHIEVE-PEDS (A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes) (opens the source in a new tab) (ClinicalTrials.gov (U.S. National Library of Medicine), Oct 18, 2026)
- Key facts from tracked records
- 23 clinical trials tracked from ClinicalTrials.gov
- 4 NPHLA briefings on this topic
What’s the latest on Orforglipron?
4 totalWhat changed today in Metabolic: 5 trial updates, 2 drug-shortage updates, 1 new study
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records9 sources1 min read
Clinical trial phases, explained: what phase 1, 2, 3 and 4 tell you
Phase labels appear in every drug-pipeline headline. Here is what each phase is designed to answer, how large the studies typically are, and what a phase label does not tell you.
AI-assisted · Editor reviewed2 sources2 min read
What changed today in Metabolic: 6 trial updates, 1 new study
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records10 sources1 min read
What do the official records show?
Primary sources and peer-reviewed research- Trial status changed to “Recruiting”: ACHIEVE-PEDS (A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes) (opens the source in a new tab)
Phase 3, Eli Lilly and Company. Previously “Not yet recruiting”. Conditions: Diabetes Mellitus, Type 2. Interventions: Orforglipron; Dulaglutide. Investigational: trial-stage therapies are not approved for the use studied.
- Results posted on ClinicalTrials.gov: ACHIEVE-2 (A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and…) (opens the source in a new tab)
Phase 3, Eli Lilly and Company. Conditions: Type 2 Diabetes. Interventions: Orforglipron; Dapagliflozin. Investigational: trial-stage therapies are not approved for the use studied.
- Trial status changed to “Active, not recruiting”: ATTAIN-OA PAIN (A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee) (opens the source in a new tab)
Phase 3, Eli Lilly and Company. Previously “Recruiting”. Conditions: Osteoarthritis. Interventions: Orforglipron; Placebo. Investigational: trial-stage therapies are not approved for the use studied.
- Results posted on ClinicalTrials.gov: ACHIEVE-5 (A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin…) (opens the source in a new tab)
Phase 3, Eli Lilly and Company. Conditions: Type 2 Diabetes. Interventions: Orforglipron; Placebo. Investigational: trial-stage therapies are not approved for the use studied.
- Results posted on ClinicalTrials.gov: ACHIEVE-3 (A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately…) (opens the source in a new tab)
Phase 3, Eli Lilly and Company. Conditions: Type 2 Diabetes. Interventions: Orforglipron; Semaglutide. Investigational: trial-stage therapies are not approved for the use studied.
- Results posted on ClinicalTrials.gov: ATTAIN-2 (A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes) (opens the source in a new tab)
Phase 3, Eli Lilly and Company. Conditions: Obesity; Overweight; Type 2 Diabetes. Interventions: Orforglipron; Placebo. Investigational: trial-stage therapies are not approved for the use studied.
Which clinical trials are being tracked?
All trials- ACHIEVE-PEDS: A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Eli Lilly and Company. Conditions: Diabetes Mellitus, Type 2. Status changed from “Not yet recruiting” on Oct 19, 2026. Investigational — not approved for the use studied.
- ATTAIN-NOW: A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Eli Lilly and Company. Conditions: Overweight; Prediabetic State; Prehypertension; Obesity, Abdominal. Investigational — not approved for the use studied.
- A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
Eli Lilly and Company. Conditions: Obesity; Overweight. Investigational — not approved for the use studied.
- RESTRAIN-SUI: A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
Eli Lilly and Company. Conditions: Urinary Incontinence,Stress. Investigational — not approved for the use studied.
- ATTAIN-PAD: Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Eli Lilly and Company. Conditions: Peripheral Arterial Disease. Investigational — not approved for the use studied.
- A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Eli Lilly and Company. Conditions: Atherosclerosis Cardiovascular Disease; Chronic Kidney Disease. Investigational — not approved for the use studied.
Industry coverage
Headlines link to the original publication- GLP-1 Pill Shows Benefit in Sleep Apnea (opens the source in a new tab)
- Lilly–Hims & Hers GLP-1 Deal Tests Whether Convenience Can Deliver Continuity of Care (opens the source in a new tab)
- FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk (opens the source in a new tab)
- Orforglipron Lowers Systolic BP in ATTAIN-1, ATTAIN-2 Analyses (opens the source in a new tab)